Comparison of SSc subjects with and without VTE. Values are n (%) unless otherwise specified.
| Characteristics | VTE, n = 40 | No VTE, n = 1141 | RR (95% CI) |
|---|---|---|---|
| Diffuse subtype | 12 (30) | 383 (34) | 1.04 (0.84–1.30) |
| Male sex | 9 (23) | 201 (18) | 1.28 (0.71–2.30) |
| Calcinosis | 10 (25) | 305 (27) | 1.00 (0.99–1.00) |
| Raynaud phenomenon | 39 (98) | 1087 (95) | 1.02 (0.97–1.08) |
| Esophageal dysmotility | 35 (88) | 981 (86) | 1.02 (0.90–1.15) |
| Telangiectasia | 29 (73) | 846 (74) | 0.98 (0.81–1.19) |
| ILD | 23 (58) | 393 (34) | 1.67 (1.26–2.20)* |
| PAH | 28 (70) | 367 (32) | 2.18 (1.75–2.71)* |
| Renal crisis | 5 (13) | 74 (6) | 1.93 (0.82–4.50) |
| Abnormal nailfold capillaries | 14 (35) | 354 (31) | 1.12 (0.73–1.74) |
| Digital ulcers | 13 (33) | 386 (34) | 0.96 (0.61–1.51) |
| Scl-70 antibody | 11 (28) | 186 (16) | 1.69 (1.00–2.84)* |
| ACA | 5 (13) | 215 (19) | 0.66 (0.29–1.52) |
| Lupus anticoagulant | (0) | 7 (0.6) | NA |
| aCL | 3 (8) | 14 (1) | 6.11 (1.83–20.4)* |
| Coronary artery disease | 9 (23) | 98 (9) | 2.62 (1.43–4.80)* |
| Hypertension | 11 (28) | 237 (21) | 1.32 (0.79–2.22) |
| Diabetes mellitus | 6 (15) | 61 (5) | 2.81 (1.29–6.10)* |
| Hyperlipidemia | 5 (13) | 78 (7) | 1.83 (0.78–4.27) |
| Peripheral arterial disease | 8 (20) | 41 (4) | 5.57 (2.79–11.08)* |
| Cancer | 7 (18) | 127 (11) | 1.57 (0.79–3.14) |
| Stroke | 2 (5) | 30 (3) | 1.90 (0.47–7.68) |
| Atrial fibrillation | 6 (15) | 45 (4) | 3.80 (1.72–8.39)* |
↵* Denotes statistical significance. VTE: venous thromboembolism; RR: relative risk; ILD: interstitial lung disease; PAH: pulmonary arterial hypertension; ACA: anticentromere antibodies; NA: not available; aCL: anticardiolipin antibodies.